Future Directions in Renal Cell Carcinoma: 2011 and Beyond
Future Directions in Renal Cell Carcinoma: 2011 and Beyond
复制标题
DOI：
10.1016/j.hoc.2011.05.001
复制
发表时间：
2011-08-01
影响因子：
2.4
通讯作者：
Atkins, Michael B.
中科院分区：
文献类型：
--
作者：
Cho, Daniel C.;Atkins, Michael B.
从主要以细胞因子为基础的时代中脱颖而出，过去几年见证了肾癌治疗格局的巨大变化。分子靶向药物和抗血管生成药物现已成为晚期肾细胞癌 (RCC) 患者大多数治疗策略的支柱。尽管未来几年可能不会出现如此广泛的范式转变，但肾细胞癌患者的护理仍有很大的改进空间。这篇综述讨论了医生和研究人员面临的挑战以及可能有助于改善肾细胞癌患者治疗结果的创新。
Emerging from a largely cytokine-based era, the last several years have witnessed a dramatic change in the therapeutic landscape of renal cancer. Molecularly targeted and antiangiogenic agents now form the backbone of most therapeutic strategies for patients with advanced renal cell carcinoma (RCC). Although the next few years may not see such broad paradigm shifts, there remains significant room for improvement in the care of patients with RCC. This review discusses challenges that face physicians and researchers as well as innovations that may contribute to improving the therapeutic outcomes for patients with RCC.